Klemens Pranz

1PUBLICATIONS
12CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

Sort by Publication Date:
|Jun 22, 2018
Afatinib restrains K-RAS-driven lung tumorigenesis.

Herwig P Moll, Klemens Pranz, Monica Musteanu

Pageof 1

Frequent Collaborators

1 joint publications

Herwig P Moll

1 joint publications

Monica Musteanu

1 joint publications

Luka Brcic

1 joint publications

Viktoria Laszlo

1 joint publications

Richard Moriggl

1 joint publications

Robert Eferl

1 joint publications

Pedro P Lopez-Casas

1 joint publications

Dagmar Stoiber

1 joint publications

Josef Penninger

1 joint publications

Balázs Dome

Frequent Collaborators

1 joint publications

Herwig P Moll

1 joint publications

Monica Musteanu

1 joint publications

Luka Brcic

1 joint publications

Viktoria Laszlo

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
See more related videos

Top Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.4K
See more related videos